Summary by Futu AI
On May 16, 2024, CVS Health Corporation conducted its 2024 Annual Meeting of Stockholders, where several key proposals were voted upon. The stockholders approved an amendment to the 2017 Incentive Compensation Plan (2017 ICP), which will increase the number of common shares available for issuance by 33.5 million. This amendment had previously received approval from the Management Planning and Development Committee and the Board of Directors, contingent on stockholder approval. The meeting also resulted in the election of 12 nominees to the Board of Directors for a one-year term, the ratification of Ernst & Young LLP as the independent registered public accounting firm for 2024, and the advisory approval of the compensation of the company's named executive officers. However, four stockholder proposals were not approved. The detailed voting results for each proposal were provided in the report. The amended 2017 ICP and the forms of award agreements to be used under the plan were filed as exhibits to the report.